• ^99m Technetium-pyrophosphate bone scan: A potential biomarker for the burden of transthyretin amyloidosis in skeletal muscle: A preliminary study
• ^99m Technetium-pyrophosphate scintigraphy: a practical guide for early diagnosis of transthyretin amyloid cardiomyopathy
• 18-Month effect of tafamidis on the progression of cardiac amyloidosis evaluated according to a multiparametric expert consensus tool
• A case of lattice corneal dystrophy type 1 with bilateral Mooren's ulcer
• A compartment-based myocardial density approach helps to solve the native T1 vs. ECV paradox in cardiac amyloidosis
• A natural history analysis of asymptomatic <em>TTR</em> gene carriers as they develop symptomatic transthyretin amyloidosis in the Transthyretin Amyloidosis Outcomes Survey (THAOS)
• A novel quantitative method for assessing the therapeutic response to Tafamidis therapy in patients with cardiac TTR amyloidosis. A preliminary report
• A novel TTR mutation (p.Ala65Val) underlying late-onset hereditary transthyretin (ATTRv) amyloidosis with mixed cardiac and neuropathic phenotype: a case report
• Advances in the treatment of transthyretin cardiac amyloidosis: Current and emerging therapies
• Age-related amyloidosis outside the brain: A state-of-the-art review
• An Arg124Cys mutation in transforming growth factor β-induced gene associated with lattice corneal dystrophy type I in a Chinese pedigree
• ANMCO Position paper: Amyloidosis for the clinical cardiologist. A "clinical primer" from the ANMCO Rare Disease Working Group
• Biochemical and biophysical properties of an unreported T96R mutation causing transthyretin cardiac amyloidosis
• Bone marrow amyloid: a comprehensive analysis of 1,469 samples, including amyloid type, clinical features, and morphologic distribution
• Cardiac Amyloidosis Imaging, Part 3: Interpretation, Diagnosis, and Treatment
• Cardiac amyloidosis in Latin America: Gaps and opportunities to increase awareness of the disease. Findings from the AMILO-LATAM research group
• Cardiac amyloidosis: Description of a series of 143 cases
• Cardiac amyloidosis: State of art in 2022
• Cardiovascular Involvement in Transthyretin Cardiac Amyloidosis
• Characteristics and natural history of early-stage cardiac transthyretin amyloidosis
• Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS)
• Classic lattice corneal dystrophy: a brief review and summary of treatment modalities
• Clinical and apparative investigation of large and small nerve fiber impairment in mixed cohort of ATTR-amyloidosis: impact on patient management and new insights in wild-type
• Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update
• Clinical and Histopathologic Characteristics and Template of the TGFBI p.(His626Arg) Missense Variant Lattice Corneal Dystrophy
• Clinical Importance of Left Atrial Infiltration in Cardiac Transthyretin Amyloidosis
• Clinical Penetrance of the Transthyretin V122I Variant in Older Black Patients With Heart Failure: The SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study
• Clinical phenotypes and genetic features of hereditary transthyretin amyloidosis patients in China
• Corneal irregularity and visual function using anterior segment optical coherence tomography in TGFBI corneal dystrophy
• Correlation Between Cardiac Images, Biomarkers, and Amyloid Load in Wild-Type Transthyretin Amyloid Cardiomyopathy
• Correlation of Quantitative ^99mTc DPD Scintigraphy With Echocardiographic Alterations in Left Atrial Parameters in Transthyretin Amyloidosis
• Cryo-EM structure of an ATTRwt amyloid fibril from systemic non-hereditary transthyretin amyloidosis
• Describing mode of death in three major cardiac amyloidosis subtypes to improve management and survival
• Design and Rationale the SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study
• Detailed phenotypic description of stromal corneal dystrophy in a large pedigree carrying the uncommon TGFBI p.Ala546Asp pathogenic variant
• Determining patterns of vascular function and structure in wild-type transthyretin cardiac amyloidosis. A comparative study
• Diagnosis of wild-type transthyretin amyloid cardiomyopathy in Japan: red-flag symptom clusters and diagnostic algorithm
• Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience
• Distribution and progression of cerebral amyloid angiopathy in early-onset V30M (p.V50M) hereditary ATTR amyloidosis
• Early Detection of Cardiac Amyloidosis in Transthyretin Mutation Carriers
• Early Diagnosis and Outcome in Patients With Wild-Type Transthyretin Cardiac Amyloidosis
• Early Experience of Tafamidis Treatment in Japanese Patients With Wild-Type Transthyretin Cardiac Amyloidosis From the Kochi Amyloidosis Cohort
• Electrical Dyssynchrony in Cardiac Amyloidosis: Prevalence, Predictors, Clinical Correlates, and Outcomes
• Evolving epidemiology of transthyretin amyloid cardiomyopathy due to increased recognition in women
• Extracardiac Biopsy Sensitivity in Transthyretin Amyloidosis Cardiomyopathy Patients With Positive ^{99 m}Tc-Labeled Pyrophosphate Scintigraphy Findings
• Familial Amyloidotic Polyneuropathy Type 1: A Hereditary Legacy
• First Norwegian case of hereditary ATTR amyloidosis with a novel transthyretin variant
• Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy
• Impact of afterload and infiltration on coexisting aortic stenosis and transthyretin amyloidosis
• Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years
• Impact of tricuspid regurgitation on survival in patients with cardiac amyloidosis
• Incidence and predictors of worsening heart failure in patients with wild-type transthyretin cardiac amyloidosis
• Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis
• Interatrial septal ^99mTc-pyrophosphate uptake and reduced strain in wild-type transthyretin amyloid cardiomyopathy
• Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Distribution in a Mexican Population
• Long-term survival in people with transthyretin amyloid cardiomyopathy who took tafamidis: A Plain Language Summary
• Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy
• Low-Carbohydrate Diet Macronutrient Quality and Weight Change
• Management Strategies for Atrial Fibrillation and Flutter in Patients with Transthyretin Cardiac Amyloidosis
• Mutation effects on FAS1 domain 4 based on structure and solubility
• Myocardial Scintigraphy in Diagnosing Cardiac Transthyretin Amyloidosis
• Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT
• Neurological manifestations of ATTR amyloidosis
• Pathological review of cardiac amyloidosis using autopsy cases in a single Japanese institution
• Peripheral nerve involvement in wild-type transthyretin amyloidosis
• Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid
• Phenotypes Associated With the Val122Ile, Leu58His, and Late-Onset Val30Met Variants in Patients With Hereditary Transthyretin Amyloidosis
• Plasmin activity promotes amyloid deposition in a transgenic model of human transthyretin amyloidosis
• Population pharmacokinetic/pharmacodynamic modelling of eplontersen, an antisense oligonucleotide in development for transthyretin amyloidosis
• Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis
• Prevalence of transthyretin-related amyloidosis in Tuscany: Data from the regional population-based registry
• Prevalence, incidence and clinical outcomes of epicardial coronary artery disease among transthyretin amyloidosis cardiomyopathy patients
• Prognostic value of exercise echocardiography in patients with wild-type transthyretin amyloidosis
• Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis
• Real-Life Evaluation of an Algorithm for the Diagnosis of Cardiac Amyloidosis
• Real-World Characteristics of Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy: An Analysis of Electronic Healthcare Records in the United States
• Regression of Myocardial ^99mTc-DPD Uptake After Tafamidis Treatment of Cardiac Transthyretin Amyloidosis
• Renal Involvement in Transthyretin Amyloidosis: The Double Presentation of Transthyretin Amyloidosis Deposition Disease
• Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis
• Right ventricular-dominant transthyretin deposition: an early stage or a rare phenotype of wild-type transthyretin amyloid cardiomyopathy?
• Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis
• Screening for Cardiac Amyloidosis 5 to 15 Years After Surgery for Bilateral Carpal Tunnel Syndrome
• Sex differences among patients with transthyretin amyloid cardiomyopathy - from diagnosis to prognosis
• Sex-related differences in the clinical characteristics of wild-type transthyretin amyloidosis cardiomyopathy
• Steep increase in the number of transthyretin-positive cardiac biopsy cases in Japan: evidence obtained by the nation-wide pathology consultation for the typing diagnosis of amyloidosis
• Strong positive light chain immunostaining in a patient with transthyretin amyloidosis
• Structural basis for transthyretin amyloid formation in vitreous body of the eye
• Surgical outcomes of re-excimer laser phototherapeutic keratectomy (re-PTK)
• Surveillance for disease progression of transthyretin amyloidosis after heart transplantation in the era of novel disease modifying therapies
• Synthesis and biological evaluation of quinolone derivatives as transthyretin amyloidogenesis inhibitors and fluorescence sensors
• Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis
• The alterations of corneal biomechanics in adult patients with corneal dystrophy
• The Association of Cardiac Biomarkers, the Intensity of Tc99 Pyrophosphate Uptake, and Survival in Patients Evaluated for Transthyretin Cardiac Amyloidosis in the Early Therapeutics Era
• Therapeutic value of tafamidis in patients with wild-type transthyretin amyloidosis (ATTRwt) with cardiomyopathy based on cardiovascular magnetic resonance (CMR) imaging
• Topical Losartan: Practical Guidance for Clinical Trials in the Prevention and Treatment of Corneal Scarring Fibrosis and Other Eye Diseases and Disorders
• Transthyretin amyloidosis and herpes zoster infection: a mimic of temporal arteritis
• Usefulness of quantitative ^99mTc-pyrophosphate SPECT/CT for predicting the prognosis of patients with wild-type transthyretin cardiac amyloidosis
• Variant Transthyretin Amyloidosis (ATTRv) in Hungary: First Data on Epidemiology and Clinical Features
• Vutrisiran: First Approval
• Wild-Type Transthyretin Amyloid Cardiomyopathy: The Gordian-Knot of Novel Therapeutic Regimens